BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 32133643)

  • 1. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
    Jin L; Zhang Y; Yang W
    Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
    Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
    Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
    Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
    J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
    Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
    Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.
    Park SJ; Yim GW; Paik H; Lee N; Lee S; Lee M; Kim HS
    J Gynecol Oncol; 2021 Sep; 32(5):e73. PubMed ID: 34132071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy.
    Bandla A; Tan S; Kumarakulasinghe NB; Huang Y; Ang S; Magarajah G; Hairom Z; Lim JSJ; Wong A; Chan G; Ngoi N; Ang E; Lee YM; Chan A; Lee SC; Thakor N; Wilder-Smith E; Sundar R
    Support Care Cancer; 2020 Aug; 28(8):3691-3699. PubMed ID: 31811482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
    Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
    Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pronociceptive Roles of Schwann Cell-Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy.
    Koyanagi M; Imai S; Matsumoto M; Iguma Y; Kawaguchi-Sakita N; Kotake T; Iwamitsu Y; Ntogwa M; Hiraiwa R; Nagayasu K; Saigo M; Ogihara T; Yonezawa A; Omura T; Nakagawa S; Nakagawa T; Matsubara K
    Cancer Res; 2021 Apr; 81(8):2207-2219. PubMed ID: 33608316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
    Chen CS; Smith EML; Stringer KA; Henry NL; Hertz DL
    Breast Cancer Res Treat; 2022 Aug; 194(3):551-560. PubMed ID: 35760975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study Protocol for Assessing the Efficacy of Compression Therapy Using Stockings and Sleeves to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients.
    Yamanouchi K; Kuba S; Matsumoto M; Yano H; Morita M; Sakimura C; Otsubo R; Kanetaka K; Nagayasu T; Eguchi S
    Acta Med Okayama; 2020 Oct; 74(5):455-459. PubMed ID: 33106704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
    Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
    Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the effect of lithium on taxane-induced neuropathy.
    Kochan DC; Novotny PJ; Cathcart-Rake EJ; Orme JJ; Tevaarwerk AJ; Ruddy KJ; Childs DS
    Support Care Cancer; 2023 Apr; 31(5):299. PubMed ID: 37097406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.